Last checked at 17 Oct 2022 07:00
RNS Number : 0213D Oxfor Cannabinoi Tech.Holings 17 October 2022 160160
17 October 2022
160
Oxfor Cannabinoi Technologies Holings plc
("OCTP" or "the Company")
160
Directorate Change
160
Further to the announcement of 26 August 2022, Oxfor Cannabinoi Technologies Holings plc, the pharmaceutical company eveloping prescription cannabinoi meicines targeting the US multi-billion pain market, announces the following Boar changes.
The Company is please to announce the appointment of Paul William Smalley as the new Group Finance Director with effect from 17 October 2022.160 He takes over from Karen Lowe who is staning own from the Boar an leaves the Company on 31 October 2022.160
160
Paul joins the Company from Panthera Biopartners Lt, a clinical trials management company where he was the Finance Director an Company Secretary overseeing financial an treasury management, as well as assisting with mergers an acquisitions.160 As a CIMA qualifie accountant, Paul has more than 2 years' UK an international financial experience incluing strategic management capabilities gaine across a wie range of market sectors, with expertise extening to IT, HR an procurement.160 He has worke in a variety of organisations, from SMEs to quote companies incluing as Finance Director of JOST UK Lt, which was a UK subsiiary of JOST Werke AG, a company quote on the Frankfurt Stock Exchange.
160
Julie Pomeroy, OCTP Non-Executive Chair sai: "We are elighte to welcome Paul to the Boar.160 He brings with him a number of years' strategic financial management experience from the life science an wier sectors, in both the UK an mainlan Europe.160 An I am sure that he will quickly become a highly value member of the OCTP team.160 We also wish Karen every success in the future an thank her wholeheartely for her commitment an contribution to OCTP. "
160
This announcement contains insie information for the purposes of Article 7 of EU Regulation 96/2014 (which forms part of omestic UK law pursuant to the European Union (Withrawal) Act 2018).
160
The Directors of the Company accept responsibility for the content of this announcement.
Enquiries:
About Oxfor Cannabinoi Technologies Holings plc:
Oxfor Cannabinoi Technologies Holings plc ("OCTP") is160the holing company of Oxfor Cannabinoi Technologies Lt ("OCT") (together the "Group"), a pharmaceutical Group eveloping prescription cannabinoi meicines for approval by key meicines regulatory agencies worlwie an targeting the U multi-billion pain market. Cannabinois are compouns foun in the cannabis plant that have been shown to have a range of therapeutic effects on the boy, incluing pain relief. The Group has a clearly efine path to commercialisation, revenues an growth. The Group is eveloping rug caniates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable meical professionals to prescribe them with confience.
The Group's portfolio aims to balance risk, value an time to market, whilst ensuring market exclusivity aroun all its key activities. The Group's lea compoun, OCT461201, is a highly potent an selective CB2 agonist an is being evelope by OCTP in a soli oral osage form. OCTP is conucting pre-clinical testing an evelopment with clinical trials scheule for Q1 2023. The Group's prouct pipeline also uses a balance rug prouct strategy that employs both natural an synthetic compouns for the treatment of rare iseases an inclues chemically moifie phytocannabinois with improve rug-like characteristics an a proprietary library of cannabinois.
OCTP operates a partnership moel with external acaemic an commercial partners.
Caution regaring forwar looking statements
Certain statements in this announcement, are, or may be eeme to be, forwar looking statements. Forwar looking statements are ienti6427e by their use of terms an phrases such as ''believe'', ''coul'', "shoul" ''envisage'', ''estimate'', ''inten'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, incluing references to assumptions. These forwar-looking statements are not base on historical facts but rather on the Directors' current expectations an assumptions regaring the Company's future growth, results of operations, performance, future capital an other expenitures (incluing the amount, nature an sources of funing thereof), competitive avantages, business prospects an opportunities. Such forwar looking statements re6428ect the Directors' current beliefs an assumptions an are base on information currently available to the Directors.
160
This information is provie by RNS, the news service of the Lonon Stock Exchange. RNS is approve by the Financial Conuct Authority to act as a Primary Information Provier in the Unite Kingom. Terms an conitions relating to the use an istribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP aress to confirm compliance with the terms an conitions, to analyse how you engage with the information containe in this communication, an to share such analysis on an anonymise basis with others as part of our commercial services. For further information about how RNS an the Lonon Stock Exchange use the personal ata you provie us, please see our Privacy Policy.160 END160160BOADGBDGDGBDGDL